AzTrials
AzTrials

Breast CancerNCT06404983

Opioid-free Anaesthesia in Breast Cancer Surgery

A study testing Opioid Free Anaesthesia (OFA) and Conventional General Anaesthesia (CGA) in people with Breast Cancer and Anesthesia, run by University of Ioannina at 1 site in Greece.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Background: Various analgesic modalities are adopted for perioperative analgesia in breast cancer surgeries. Opioid-free and opioid-sparing techniques are gaining popularity due to the lack of opioid-dependent undesirable effects, including respiratory depression, urinary retention, nausea and vomiting, constipation… Read more about this study

Who is it for?
Ages 18 to 99 years, women only
Conditions the study is for
Breast Cancer, Anesthesia, Pain, Postoperative
What is being tested?
Opioid Free Anaesthesia (OFA) and Conventional General Anaesthesia (CGA)
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteGreece
Study dates
28 Dec 2022to 12 Sep 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • adult patients
  • breast cancer surgery (mastectomy, lumpectomy, with or without lymph node excision) under general anaesthesia

Who cannot join

  • under 18 years
  • patient refusal
  • opioid use (systemic or not) for any reason (e.g., chronic malignant pain)
  • language barrier (difficulty in communicating in Greek language)
  • allergy to the administered agents
  • severe arrhythmia or other serious cardiac disease
  • severe liver and kidney failure
  • dementia, psychiatric diseases, and/or preoperative cognitive impairment

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Agathi Karakosta contact

+306948066243

akarakosta@uoi.gr

Gloria-Evdoxia Izountouemoi contact

+306982799750

gloriaizou@gmail.com

Greece1 site, 1 recruiting
  • University Hospital of Ioannina

    Ioannina, Epirus, 455 00

    Agathi Karakosta, +306948066243, akarakosta@uoi.gr

    Gloria-Evdoxia Izountouemoi, +306982799750, gloriaizou@gmail.com

    Recruiting

Other trials in Greece

About this study

Official title: A Comparative Evaluation of Opioid Free Anaesthesia Technique Versus the Conventional Technique in Oncological Breast Surgery

Background:

Various analgesic modalities are adopted for perioperative analgesia in breast cancer surgeries. Opioid-free and opioid-sparing techniques are gaining popularity due to the lack of opioid-dependent undesirable effects, including respiratory depression, urinary retention, nausea and vomiting, constipation, itching, opioid-induced hyperalgesia, tolerance, addiction, and immune system disorders.

Read more

The goal of this prospective randomized clinical trial is to investigate the impact of opioid-free anaesthesia (OFA) versus conventional general anaesthesia (CGA) on postoperative analgesic requirements after breast cancer surgery (lumpectomy/mastectomy, with or without axillary lymph node excision).

Secondary objectives include comparative perioperative evaluation of cognitive function and postoperative adverse events during the first 48 hours atfter surgery. Comparative evaluation of intraoperative haemodynamics and hospital length of stay are also secondary objectives, as well as the incidence of neuropathic pain assessed by validated questionnaires at 3 and 6 months postoperatively.

During the preoperative screening, body measurements, age, gender, ASA (American Society of Anesthesiologists) physical status classification, educational level (using a 6-level scale: elementary, middle school, high school, higher education, higher education, and postgraduate/doctoral degree), home medication, and comorbidities (using the Charlson Comorbidity Index) are recorded.

Intraoperatively, the duration of anaesthesia, duration of surgery, associated intraoperative data (e.g., haemodynamic instability, adverse effects associated with protocol-administered pharmaceutical agents, etc.), and medications administered (type and quantity) are recorded.

The investigators expect to recruit at least 100 participants per group.

Read the detailed description

INTRODUCTION. Opioids are the mainstay for achieving analgesia in the perioperative setting. Standard anaesthetic practice in breast cancer surgery involves balanced general anaesthesia with the use of opioids intra- and postoperatively. Opioid-free anaesthesia (OFA) is a relatively recent anaesthetic proposal whereby no opioid is administered intraoperatively (systemically, in neuraxial or peripheral block or intra-cavity) and the use of opioids is avoided throughout the perioperative period.

Non-opioid anaesthesia appears to provide adequate postoperative analgesia while protecting the patient from the side effects of opioids, which include respiratory depression, opioid-induced hyperalgesia, postoperative nausea/vomiting, cognitive dysfunction, etc. Recently, concerns have arisen regarding delayed healing, immunosuppression, and worsening of oncological outcomes in cancer patients due to the systemic use of opioids.

Side effects of opioids include:

  • Respiratory depression
  • Muscle stiffness
  • Weakness of pharyngeal muscles
  • Upper airway obstruction (muscle atony)
  • Negative inotropic action
  • Nausea, vomiting
  • Ileus, constipation
  • Urinary retention
  • Tolerance and addiction
  • Dizziness
  • Excessive drowsiness and sleep disorder

BACKGROUND. During the past decade there has been a growing interest in opioid sparing and opioid free techniques for general anaesthesia. The international literature started to be enriched with interesting cases and small prospective studies supporting the benefits of this technique, especially in patients with morbid obesity. According to its proponents, this technique is characterized by: 1) sympatholysis, analgesia, and anaesthesia (MAC reduction) using dexmedetomidine, 2) analgesia with low-dose of ketamine, 3) administration of lidocaine adjunctively for anaesthesia and sympatholysis, 4) deep neuromuscular blockade until the end of the procedure, 5) use of sevoflurane or desflurane 0.7 to 1 MAC in O2/air and titration based on entropy or BIS monitoring and 6) administration of magnesium adjunctively for analgesia. Inadequate sympatholysis is corrected by titrated doses of clonidine, whereas excessive sympatholysis is treated by the administration of vasoconstrictors, preferably ephedrine because of its chronotropic action. In addition, dexamethasone, high-dose paracetamol, NSAIDs, and gabapentin can be used adjunctively in the context of multimodal management of surgical pain.

However, the OFA method is not without its disadvantages, of which the clinician should be aware. Ketamine can disrupt electrocerebral monitoring (e.g., BIS) for possible intraoperative vigilance, although according to the proponents of the method, intraoperative vigilance is only a possibility in incorrect use of the technique, and they argue that it is unlikely to occur if BIS is maintained below 60. The need for hemodynamic support with vasoconstrictor administration is an additional disadvantage, and there may be a need to infringe the OFA protocol to achieve ideal intubation conditions using small doses of short-acting opioids during induction of anesthesia. Also, a significant degree of cutaneous vasoconstriction may be observed, an expected a2 action of concern to the clinician. Finally, training of the nursing staff and familiarity with the method is required.

Despite the above disadvantages of the method, OFA is becoming increasingly popular because of its excellent management of postoperative pain, protecting the patient from surgical and opioid-induced hyperalgesia, and because of the minimization of the risk of respiratory depression in high-risk patients (COPD, sleep apnea, morbid obesity, etc.).

The prevalence of chronic postoperative pain after breast cancer surgery (mastectomy, lumpectomy, with or without lymph node excision) is high and according to recent reports is 29.8%. The OFA technique has been studied in breast cancer surgery. However, these are mostly small studies examining the efficacy of this technique in acute postoperative pain. The effect of the OFA technique on chronic pain after breast cancer surgery has not been studied so far.

GOAL OF STUDY. The primary objective of the study is to evaluate postoperative analgesia for breast cancer surgery of low and intermediate severity (mastectomy, lumpectomy, with or without lymph node excision). Specifically, this is a prospective comparative study of pain intensity and total postoperative consumption of opioids and other analgesics in patients who received general anesthesia under OFA protocol (OFA group) versus those who received general anesthesia using opioids (CGA group, conventional General Anaesthesia).

Secondary objectives are the evaluation of intraoperative haemodynamic stability by recording the total use of vasoactive substances, time of extubation, length of stay in the Post-Anesthesia Care Unit (PACU), and total length of hospitalization per study group. In addition, secondary objectives include the comparative recording of serious postoperative anaesthesia-related adverse events (postoperative hypoxaemia, postoperative ileus, nausea/vomiting, etc.) and the comparative study of cognitive function in the perioperative period.

As part of the second part of the study, all participants will be monitored for the development of postoperative chronic pain using specific tools. Chronic postsurgical pain assessment will be performed at 3 and 6 months postoperatively.

METHOD. The anaesthetic technique of the OFA group is based on the protocol of Mulier et al. The intraoperative management of the CGA group will follow standard clinical protocols. All patients will give written informed consent to be included in the study.

During the preoperative screening, somatometrics, age, gender, ASA (American Society of Anesthesiologists) physical status classification, educational level (using a 6-level scale: elementary, middle school, high school, higher education, higher education, and postgraduate/doctoral degree), home medication, and comorbidities (using the Charlson Comorbidity Index) are recorded.

Intraoperatively, the duration of anaesthesia, duration of surgery, and associated intraoperative data (e.g., haemodynamic instability, adverse effects associated with protocol-administered pharmaceutical agents, etc.) and medications administered (type and quantity) are being recorded.

The length of stay in the Post Anaesthesia Care Unit (PACU) and the length of stay in the hospital shall also be recorded. Serious adverse events related to general anaesthesia for 48 hours post-operatively shall be recorded.

The intensity of acute postoperative pain shall be assessed using the NRS (Numerical Rating Scale) scale (Numerical Rating Scale, 0-10) at predefined intervals up to 48 hours postoperatively.

Participants' cognitive status, chronic postoperative pain, depression, anxiety, stress, and satisfaction will be assessed using validated questionnaires at 3 and 6 months after surgery.

STATISTICAL ANALYSIS. This is a prospective single-blind randomized clinical trial. Randomization will be carried out using sealed envelopes sorted based on computer-generated random numbers (Random Allocation Software).

Sample size calculation is based on a pilot study of 20 consecutive participants that was carried out in the University Hospital of Ioannina, with the primary outcome beeing the difference in NRS between groups at 1, 6, and 12 hours postoperatively, both at rest and at a deep breath.

Participant recruitment is expected to take up to 2 years, and the investigators expect to enroll at least 100 patients per study group.

Data analysis will be performed using Stata™ software (Version 10.1 MP, Stata Corporation, College Station, TX 77845, USA).

Being tested
Opioid Free Anaesthesia (OFA), Conventional General Anaesthesia (CGA)
Medical subject headings
Breast Neoplasms, Pain, Postoperative, Chronic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Opioid Free Anaesthesia (OFA)Other

    Also called N.O.A.M (non-opioid anaesthetic mixture: dexmedetomidine, ketamine and lidocaine)

    Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.

  • Conventional General Anaesthesia (CGA)Other

    Also called O.A.M. (Opioid Anaesthetic Mixtute: fentanyl, morphine)

    Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.

Study groups in NCT06404983
Study groupRoleWhat they receive
Opioid Free Anaesthesia (OFA group)ExperimentalPatients are randomly allocated to receive non-opioid anaesthesia. Intraoperative analgesia will be achieved by continuous intravenous administration of a mixture of dexmedetomidine, ketamine, and lidocaine.
Receives: Other: Opioid Free Anaesthesia (OFA)
Conventional general anaesthesia (CGA group)Active comparatorPatients are randomly allocated to receive conventional general anaesthesia with intraoperative use of opioids at the discretion of the attending anaesthesiologist.
Receives: Other: Conventional General Anaesthesia (CGA)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative analgesia.

    Postoperative level of analgesia assessed by the NRS (Numerical Rating Scale, ranging from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable).

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  2. Postoperative consumption of opioids.

    Total postoperative consumption of opioids.

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

Secondary outcomes (17)
  1. Perioperative blood pressure measurements.

    Intermittent blood pressure measurements (every 5 minutes) - blood pressure measured in mmHg.

    Measured: From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

  2. Perioparative pulse measurements.

    Intermittent arterial pulse measurements (every 5 minutes) - measured in beats per minute.

    Measured: From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

  3. Perioperative consumption of ephedrine.

    Total intravenous consumption of ephedrine, measured in milligrams.

    Measured: From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

  4. Perioperative consumption of atropine.

    Total intravenous consumption of atropine, measured in milligrams.

    Measured: From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

  5. Perioperative consumption of phenylephrine.

    Total intravenous consumption of phenylephrine, measured in milligrams.

    Measured: From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

  6. PACU (Post Anaesthesia Care Unit) length of stay.

    Minutes from PACU (Post Anaesthesia Care Unit) admission to PACU discharge.

    Measured: From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

  7. Duration from end of anaesthesia to extubation.

    Minutes from anaesthetic drug discontinuation to removal of endotracheal tube from the patient.

    Measured: From end of anaesthesia, defined by anaesthetic drug discontinuation, to removal of endotracheal tube, assessed up to 48 hours.

  8. Postoperative episodes of nausea and/or vomiting.

    Number of participants with postoperative recording of episodes of nausea/vomiting.

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  9. Postoperative pruritus.

    Number of participants with postoperative recording of pruritus.

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  10. Postoperative paralytic ileus.

    Number of participants with postoperative clinical signs of paralytic ileus.

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  11. Postoperative respiratory depression.

    Number of participants with postoperative recording of hypoxaemic episodes (SpO2<90% with FiO2 (fraction of inspired oxygen) 21%)

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  12. Postoperative sedation.

    Number of participants with postoperative sedation measured with the Ramsay Sedation Scale (ranging from +4 (a violent dangerous patient) to -5 (an unarousable patient)).

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  13. Postoperative headache.

    Number of participants with postoperative episodes of headache, as assessed in a 4 rating scale (0: no headache to 3: severe headache).

    Measured: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

  14. Postoperative neuropathic pain assessed by the S-LANSS pain score.

    Number of participants with postoperative neuropathic pain assessed by the use of the S-LANSS pain score (ranging from 0 to 24 points, where ≥12 points suggest the presence of neuropathic pain symptomatology).

    Measured: From hospital discharge until 6 months postoperatively.

  15. Postoperative neuropathic pain assessed by the McGill questionnaire.

    Number of participants with postoperative neuropathic pain assessed by the use of the McGill questionnaire (The present pain intensity (PPI) is based on a scale of 0-5, with 0 meaning no pain).

    Measured: From hospital discharge until 6 months postoperatively.

  16. Postoperative depression and anxiety.

    Number of participants with postoperative depression and anxiety assessed by the use of DASS21 tool, which is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress (the greater the score the greater the risk for depression, anxiety and stress).

    Measured: From hospital discharge until 6 months postoperatively.

  17. Postoperative cancer recurrence.

    Number of participants with postoperative cancer recurrence as assessed by examination of patient records (clinical examination, imaging testing, laboratory testing and biopsies that are part of the patient's follow-up protocol).

    Measured: From hospital discharge to 5 years postoperatively.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2024
  2. Study start28 Dec 2022
  3. Primary completion20 Dec 2026 (estimated)
  4. Study completion12 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06404983
Sponsor's protocol ID
27
Status last verified
May 2026
First submitted
27 Mar 2024
Last updated
6 May 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication.

Publications

  • Wang K, Yee C, Tam S, Drost L, Chan S, Zaki P, Rico V, Ariello K, Dasios M, Lam H, DeAngelis C, Chow E. Prevalence of pain in patients with breast cancer post-treatment: A systematic review. Breast. 2018 Dec;42:113-127. doi: 10.1016/j.breast.2018.08.105. Epub 2018 Sep 4.

    PubMed 30243159

Questions about this trial

What is this clinical trial studying?

A study testing Opioid Free Anaesthesia (OFA) and Conventional General Anaesthesia (CGA) in people with Breast Cancer and Anesthesia, run by University of Ioannina at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Agathi Karakosta (+306948066243, akarakosta@uoi.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative analgesia. (time frame: From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06404983, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in